Tumblr Fave Likes Y...
Health Care: Drugs
Galectin Therapeutics Inc (GALT: NASDAQ)
$4.44 0.02 | 0.34%
05/21/13 - 12:33 PM ET
20.77K / 92.70K
Vol / Avg. Vol:4.37 / 4.42
Open / Prev. Close:4.32 - 4.44
Today's Range:1.60 - 5.22
52 Wk Range:114.63%
Performance YTD:TheStreet Rating:
Portfolios with GALT
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
Latest GALT Headlines from TheStreet
- 4 Stocks Under $10 Spiking Higher 03.05.13 | 02:03 pm
- Marvell and Galileo: Who's Buying Whom? 10.18.00 | 12:10 pm
- Marvell Technology Plunges After Deal to Buy Galileo 10.17.00 | 04:10 pm
- Galileo Surges 39% on Merger by Marvell Technology 10.17.00 | 09:10 am
- Marvell Buying Galileo in $2.7 Billion Communications Chips Deal 10.17.00 | 08:10 am
Press Releases for GALT
- Galectin Therapeutics To Present New Data On The Treatment Of Liver Fibrosis And Cirrhosis - PR Newswire 04.17.13 | 08:04 am
- Clinical Trial Sites For First Human Clinical Trial For Treatment Of Fatty Liver Disease With Advanced Fibrosis Announced By Galectin Therapeutics - PR Newswire 04.09.13 | 10:04 am
- Galectin Therapeutics: Turning Atlanta Into America's Next Silicon Valley - PR Newswire 04.04.13 | 08:04 am
- Galectin Therapeutics: Turning Atlanta Into America's Next Silicon Valley - PR Newswire 04.04.13 | 08:04 am
- Galectin Therapeutics Inc. Receives OK From FDA To Proceed With First Human Clinical Trial For Treatment Of Fatty Liver Disease With Advanced Fibrosis - PR Newswire 03.05.13 | 09:03 am
- Galectin Therapeutics Announces Discovery Program For New Anti-Galectin Drugs In Collaboration With The University Of Georgia - Business Wire 02.19.13 | 09:02 am
- Galectin Therapeutics Executive Chairman, James Czirr To Appear On “The RedChip Money Report” On FOX Business News - Business Wire 02.07.13 | 05:02 pm
- Galectin Therapeutics Inc. Announces Submission Of An Investigational New Drug (IND) Application For The Treatment Of Fatty Liver Disease - Business Wire 01.31.13 | 09:01 am
- Galectin Therapeutics Inc. Announces Publication Of Galectin Symposium Proceedings By The American Chemical Society - Business Wire 01.28.13 | 09:01 am
- New Potential Therapy For Diabetic Kidney Disease: Galectin Therapeutics Announces Anti-Galectin Drug Is Effective In Preclinical Studies - Business Wire 01.22.13 | 09:01 am
Partner Headlines for GALT
- Galectin Therapeutics Names Shlevin COO - Benzinga 08.29.12 | 09:08 am
- Galectin Therapeutics Pops 50% on U.S. Patent - Benzinga 07.23.12 | 09:07 am
- Galectin Therapeutics Receives U.S. Patent for Potential Ground-Breaking Treatment for Chronic Liver Disease with Fibrosis and Cirrhosis - Benzinga 07.23.12 | 09:07 am
